Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001638599-19-000877
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-20 16:28:49
Reporting Period:
2019-09-20
Accepted Time:
2019-09-20 16:28:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1087939 Julian Baker 860 Washington Street, 3Rd Floor
New York NY 10014
Yes No Yes No
1087940 Felix Baker 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
1263508 Baker Bros. Advisors Lp 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
1363364 Baker Brothers Life Sciences Lp 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
1551139 667, L.p. 860 Washington Street, 3Rd Floor
New York NY 10014
Yes No Yes No
1580575 Baker Bros. Advisors (Gp) Llc 860 Washington Street
3Rd Floor
New York NY 10014
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-20 68,475 $40.00 3,383,621 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2019-09-20 1,494,025 $40.00 37,470,965 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 102,876 Direct
Common Stock 102,876 Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Common Stock Warrant (right to buy) $0.01 2013-06-07 1,569 1,569 Direct
Common Stock Common Stock Warrant (right to buy) $0.01 2013-06-07 1,569 1,569 Direct
Common Stock Common Stock Warrant (right to buy) $0.01 2013-06-07 42,131 42,131 Indirect
Common Stock Common Stock Warrant (right to buy) $0.01 2013-06-07 447,138 447,138 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
1,569 1,569 Direct
1,569 1,569 Direct
42,131 42,131 Indirect
447,138 447,138 Indirect
Footnotes
  1. Common stock ("Common Stock") of ACADIA Pharmaceuticals Inc. (the "Issuer") held directly by Felix J. Baker received from in-kind pro rata distributions without consideration.
  2. Common Stock held directly by Julian C. Baker received from the in-kind pro rata distributions without consideration.
  3. 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 68,475 and 1,494,025 shares of Common Stock, respectively, for $40.00 per share in an underwritten public offering (the "Offering") that closed on September 20, 2019.
  4. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  5. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock of the Issuer reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  6. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
  7. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  8. Represents warrants to purchase Common Stock at an exercise price of $0.01 per share with no expiration date ("Prefunded Warrants").
  9. Reflects Prefunded Warrants held directly by Julian C. Baker received in an in-kind pro rata distribution without consideration.
  10. Reflects Prefunded Warrants held directly by Felix J. Baker received in an in-kind pro rata distribution without consideration.
  11. As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Prefunded Warrants reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  12. As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Prefunded Warrants reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.